Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Guidance for Reagents for Detection of Specific Novel Influenza A Viruses, 15420 [E6-4427]
Download as PDF
<![CDATA[
cprice-sewell on PROD1PC66 with NOTICES
15420
Federal Register / Vol. 71, No. 59 / Tuesday, March 28, 2006 / Notices
caused or contributed to death or
serious injury or has malfunctioned in
such a way that should the malfunction
recur, it would be likely to cause or
contribute to a death or serious injury.
Device importers report deaths and
serious injuries to the manufacturers
and FDA. Importers report malfunctions
only to the manufacturers, unless they
are unknown, then the reports are sent
to FDA.
The number of respondents for each
CFR section in table 1 of this document
is based upon the number of
respondents entered into FDA’s internal
databases. FDA estimates, based on its
experience and interaction with the
medical device community, that all
reporting CFR sections are expected to
take 1 hour to complete, with the
exception of § 803.19. Section 803.19 is
expected to take approximately 3 hours
to complete, but is only required for
reporting the summarized data quarterly
to FDA. By summarizing events, the
total time used to report for this section
is reduced because the respondents do
not submit a full report for each event
they report in a quarterly summary
report.
The agency believes that the majority
of manufacturers, user facilities, and
importers have already established
written procedures to document
complaints and information to meet the
medical device reporting (MDR)
requirements as part of their internal
quality control system. There are an
estimated 30,000 medical device
distributors. Although they do not
submit MDR reports, they must
maintain records of complaints, under
§ 803.18(d).
The agency has estimated that on
average, 220 user facilities, importers,
and manufacturers would annually be
required to establish new procedures, or
revise existing procedures, in order to
comply with this provision.
Therefore, FDA estimates the onetime burden to respondents for
establishing or revising procedures to be
2,200 hours (220 respondents x 10
hours). For those entities, a one-time
burden of 10 hours is estimated for
establishing written MDR procedures.
The remaining manufacturers, user
facilities, and importers, not required to
revise their written procedures to
comply with this provision, are
excluded from the burden because the
recordkeeping activities needed to
comply with this provision are
considered ‘‘usual and customary’’
under 5 CFR 1320.3(b)(2).
The annual burden for recordkeeping
to respondents follows. Under § 803.17,
FDA estimates 220 respondents will
spend approximately 3.3 hours to
VerDate Aug<31>2005
15:19 Mar 27, 2006
Jkt 208001
complete the requirements for this
section. The number of respondents was
estimated by consolidating the total of
all new reporting entities together. The
3.3 hours was estimated by FDA, as this
section deals with a respondent creating
new MDR procedures and is a one-time
function. The ‘‘total hours’’ for this
section equals approximately 726 hours.
Under § 803.18, 30,000 respondents
represent distributors, importers, and
other respondents to this information
collection. FDA estimates that it should
take them approximately 1 1/2 hours to
complete the recordkeeping requirement
for this section. Total hours for this
section equal 45,000 hours.
Dated: March 20, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E6–4426 Filed 3–27–06; 8:45 am]
Dated: March 20, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E6–4427 Filed 3–27–06; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2005N–0508]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Survey of Health
Care Practitioners Regarding Their
Preferences for Public Health
Notifications
AGENCY:
ACTION:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2006N–0118]
Agency Information Collection
Activities; Announcement of Office of
Management and Budget Approval;
Guidance for Reagents for Detection of
Specific Novel Influenza A Viruses
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a collection of information entitled
‘‘Guidance for Reagents for Detection of
Specific Novel Influenza A Viruses’’ has
been approved by the Office of
Management and Budget (OMB) under
the Paperwork Reduction Act of 1995.
FOR FURTHER INFORMATION CONTACT:
Karen Nelson, Office of Management
Programs (HFA–250), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–827–1482.
An agency
may not conduct or sponsor, and a
person is not required to respond to, a
collection of information unless it
displays a currently valid OMB control
number. OMB has now approved the
information collection and has assigned
OMB control number 0910–0584. The
approval expires on September 30,
2006. A copy of the supporting
statement for this information collection
is available on the Internet at https://
www.fda.gov/ohrms/dockets.
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00049
Fmt 4703
Food and Drug Administration,
HHS.
BILLING CODE 4160–01–S
Sfmt 4703
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by April 27,
2006.
OMB is still experiencing
significant delays in the regular mail,
including first class and express mail,
and messenger deliveries are not being
accepted. To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: Fumie Yokota, Desk Officer
for FDA, FAX: 202–395–6974.
FOR FURTHER INFORMATION CONTACT:
Denver Presley, Office of Management
Programs (HFA–250), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–827–1472.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
ADDRESSES:
Survey of Health Care Practitioners
Regarding Their Preferences for Public
Health Notifications (PHNs)
The PHN is one of the tools that the
Center for Devices and Radiological
Health (CDRH) uses to get an important
message to the user community about
risks associated with the use of medical
devices. This particular tool is meant to
serve a specific purpose not served by
the other communication tools at our
E:\FR\FM\28MRN1.SGM
28MRN1
]]>Agencies
[Federal Register Volume 71, Number 59 (Tuesday, March 28, 2006)]
[Notices]
[Page 15420]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-4427]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 2006N-0118]
Agency Information Collection Activities; Announcement of Office
of Management and Budget Approval; Guidance for Reagents for Detection
of Specific Novel Influenza A Viruses
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
collection of information entitled ``Guidance for Reagents for
Detection of Specific Novel Influenza A Viruses'' has been approved by
the Office of Management and Budget (OMB) under the Paperwork Reduction
Act of 1995.
FOR FURTHER INFORMATION CONTACT: Karen Nelson, Office of Management
Programs (HFA-250), Food and Drug Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301-827-1482.
SUPPLEMENTARY INFORMATION: An agency may not conduct or sponsor, and a
person is not required to respond to, a collection of information
unless it displays a currently valid OMB control number. OMB has now
approved the information collection and has assigned OMB control number
0910-0584. The approval expires on September 30, 2006. A copy of the
supporting statement for this information collection is available on
the Internet at https://www.fda.gov/ohrms/dockets.
Dated: March 20, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E6-4427 Filed 3-27-06; 8:45 am]
BILLING CODE 4160-01-S
